Brevan Howard Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brevan Howard Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.39M	Buy	26,572 +13,836	+109%	+$1.73M	0.03%	369
2025 Q4	$1.55M	Buy	+12,736	New	+$1.46M	0.02%	581
2025 Q1	–	Sell	-22,764	Closed	-$2.05M	–	1509
2024 Q4	$2.05M	Sell	22,764 -51,750	-69%	-$5.01M	0.01%	279
2024 Q3	$7.36M	Buy	74,514 +42,025	+129%	+$4.13M	0.05%	89
2024 Q2	$3.01M	Buy	+32,489	New	+$2.91M	0.03%	143

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Brevan Howard Capital Management's XBI Position: Q1 2026 in Review

Brevan Howard Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 109% in Q1 2026, buying an estimated $1.73M and bringing the position to 26,572 shares worth $3.39M. The position accounts for 0.03% of the portfolio, ranked #369.

Brevan Howard Capital Management first reported a position in XBI in Q2 2024 and has held it in 5 quarters since. The position peaked at $7.36M in Q3 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Brevan Howard Capital Management held 26,572 shares of State Street SPDR S&P Biotech ETF worth $3.39M as of Q1 2026.
Brevan Howard Capital Management bought 13,836 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.73M.
State Street SPDR S&P Biotech ETF made up 0.03% of Brevan Howard Capital Management's portfolio in Q1 2026, its #369 holding.
Brevan Howard Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2024 and has held it in 5 quarters since.
Brevan Howard Capital Management's State Street SPDR S&P Biotech ETF position peaked at $7.36M in Q3 2024.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.